AstraZeneca plc (AZN) Shares Bought by Naples Global Advisors LLC

Naples Global Advisors LLC boosted its stake in AstraZeneca plc (NYSE:AZN) by 6.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 30,133 shares of the company’s stock after acquiring an additional 1,752 shares during the quarter. Naples Global Advisors LLC’s holdings in AstraZeneca were worth $1,046,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in AZN. Russell Investments Group Ltd. grew its stake in AstraZeneca by 198.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,856,140 shares of the company’s stock valued at $62,883,000 after acquiring an additional 1,235,239 shares during the period. Sector Gamma AS acquired a new stake in AstraZeneca during the 3rd quarter worth $25,094,000. Janus Henderson Group PLC boosted its stake in AstraZeneca by 5,754.0% during the 3rd quarter. Janus Henderson Group PLC now owns 726,599 shares of the company’s stock worth $24,617,000 after purchasing an additional 714,187 shares during the last quarter. Voya Investment Management LLC boosted its stake in AstraZeneca by 38.2% during the 2nd quarter. Voya Investment Management LLC now owns 2,395,465 shares of the company’s stock worth $81,661,000 after purchasing an additional 662,481 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in AstraZeneca by 103.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,224,939 shares of the company’s stock worth $41,501,000 after purchasing an additional 621,831 shares during the last quarter. 14.75% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca plc (NYSE AZN) traded up $0.37 during midday trading on Friday, hitting $35.44. The stock had a trading volume of 2,526,646 shares, compared to its average volume of 3,310,917. AstraZeneca plc has a fifty-two week low of $26.51 and a fifty-two week high of $35.92. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94. The stock has a market cap of $88,630.00, a price-to-earnings ratio of 25.31, a PEG ratio of 2.59 and a beta of 0.76.

AstraZeneca (NYSE:AZN) last posted its quarterly earnings results on Thursday, November 9th. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.57 by $0.55. AstraZeneca had a return on equity of 34.02% and a net margin of 15.90%. The business had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter in the previous year, the firm earned $1.32 EPS. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. equities research analysts expect that AstraZeneca plc will post 1.9 earnings per share for the current fiscal year.

Several equities research analysts have issued reports on the stock. Citigroup raised shares of AstraZeneca to a “buy” rating in a research note on Wednesday, October 18th. Zacks Investment Research cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. BMO Capital Markets set a $38.00 target price on shares of AstraZeneca and gave the stock a “buy” rating in a research note on Tuesday, October 31st. Sanford C. Bernstein raised shares of AstraZeneca from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $30.00 to $39.00 in a research note on Friday, September 22nd. Finally, JPMorgan Chase & Co. raised shares of AstraZeneca from a “neutral” rating to an “overweight” rating in a research note on Friday, December 29th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have assigned a buy rating to the stock. AstraZeneca has an average rating of “Hold” and a consensus target price of $34.48.

TRADEMARK VIOLATION NOTICE: This story was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3146152/astrazeneca-plc-azn-shares-bought-by-naples-global-advisors-llc.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.